Associations between non-insulin-based insulin resistance indices and heart failure prevalence in overweight/obesity adults without diabetes mellitus: evidence from the NHANES 2001-2018.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X (Electronic) Linking ISSN: 1476511X NLM ISO Abbreviation: Lipids Health Dis Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2002-

Heart Failure*/epidemiology ; Heart Failure*/blood ; Insulin Resistance* ; Nutrition Surveys* ; Obesity*/epidemiology ; Obesity*/blood ; Overweight*/epidemiology ; Overweight*/blood ; Triglycerides*/blood; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Blood Glucose/metabolism ; Cholesterol, HDL/blood ; Cross-Sectional Studies ; Logistic Models ; Prevalence

Background: The triglyceride glucose (TyG) index and triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio are recognized as simple non-insulin-based insulin resistance indices. Our study aimed to explore the relationship between these two indicators and heart failure (HF) in overweight or obesity individuals without diabetes.
Methods: This cross-sectional study selected 13,473 participants from the National Health and Nutrition Examination Survey (NHANES) 2001-2018 dataset. Weighted multivariable logistic regression and subgroup analysis were employed to evaluate the relationships between TyG index, TG/HDL-C ratio, and HF prevalence, respectively. Additionally, smooth curve fitting was utilized to analyze the dose-response relationships.
Results: A total of 13,473 obesity or overweight people without diabetes were included in this study through screening, among whom 291 (2.16%) had comorbid HF. The results of multivariable logistic regression suggested that the highest TyG index (OR = 2.4, 95% CI = 1.4-4.2, p = 0.002) and the highest TG/HDL-C ratio (OR = 1.2, 95% CI = 1.1-1.3, p < 0.001) both increased the prevalence of HF, especially in the non-Hispanic population. Dose-response relationships suggested nonlinear relationships between these two indicators and HF.
Conclusion: Our study demonstrated that elevated TyG index and TG/HDL-C ratio were closely associated with the prevalence of HF, and both exhibited nonlinear relationships with HF prevalence in overweight/obesity adults without diabetes. Based on these findings, additional prospective studies are needed for further validation.
(© 2024. The Author(s).)

Cardiovasc Diabetol. 2022 Nov 3;21(1):229. (PMID: 36329456)
Am J Epidemiol. 2004 Aug 15;160(4):376-83. (PMID: 15286023)
Int J Cardiol. 2019 Jan 15;275:89-94. (PMID: 30340851)
J Am Heart Assoc. 2018 Sep 4;7(17):e009890. (PMID: 30371168)
Hypertension. 1995 Jan;25(1):30-6. (PMID: 7843750)
BMJ Open. 2021 Mar 22;11(3):e041519. (PMID: 33753431)
J Am Coll Cardiol. 2008 May 6;51(18):1775-83. (PMID: 18452784)
Heart Fail Clin. 2012 Oct;8(4):609-17. (PMID: 22999243)
J Am Coll Cardiol. 1997 Aug;30(2):527-32. (PMID: 9247528)
Diabetes Metab Syndr Obes. 2020 Oct 23;13:3925-3936. (PMID: 33122929)
Metabolism. 1991 Sep;40(9):972-7. (PMID: 1895963)
Eur J Heart Fail. 2015 Oct;17(10):1015-21. (PMID: 26198713)
J Am Heart Assoc. 2021 Apr 6;10(7):e019323. (PMID: 33754795)
Cardiovasc Diabetol. 2023 Sep 7;22(1):244. (PMID: 37679763)
Cardiovasc Diabetol. 2019 Jun 12;18(1):79. (PMID: 31189473)
Diabetes. 1994 Jul;43(7):897-902. (PMID: 8013754)
Diabetologia. 2011 Mar;54(3):523-6. (PMID: 21107522)
Front Med. 2013 Mar;7(1):14-24. (PMID: 23471659)
Eur Heart J. 2000 Aug;21(16):1368-75. (PMID: 10952826)
Diabetes Metab. 2022 Nov;48(6):101365. (PMID: 35660526)
Eur J Prev Cardiol. 2022 Aug 22;29(11):1531-1541. (PMID: 35512245)
Cardiovasc Diabetol. 2023 Sep 4;22(1):239. (PMID: 37667253)
Cardiovasc Diabetol. 2021 Aug 19;20(1):170. (PMID: 34412646)
Heart Vessels. 2019 Feb;34(2):227-236. (PMID: 30140959)
N Engl J Med. 2017 Jul 6;377(1):13-27. (PMID: 28604169)
Biomed Pharmacother. 2019 Jan;109:639-645. (PMID: 30404071)
Diabetes Care. 2011 Aug;34(8):1869-74. (PMID: 21730284)
Am J Hypertens. 2005 May;18(5 Pt 1):731-7. (PMID: 15882558)
Circulation. 2000 Jun 6;101(22):2595-600. (PMID: 10840010)
J Card Fail. 2010 Sep;16(9):761-8. (PMID: 20797600)
Eur J Heart Fail. 2022 Jun;24(6):1139-1141. (PMID: 35502564)
Cardiovasc Diabetol. 2022 May 14;21(1):75. (PMID: 35568879)
Ann Intern Med. 2003 Nov 18;139(10):802-9. (PMID: 14623617)
Diagnostics (Basel). 2023 Mar 01;13(5):. (PMID: 36900073)
JACC Heart Fail. 2013 Dec;1(6):531-6. (PMID: 24455475)
Diabetes Care. 2024 Jan 1;47(Suppl 1):S20-S42. (PMID: 38078589)
Circulation. 1997 Oct 21;96(8):2520-5. (PMID: 9355888)
Circulation. 2007 Aug 7;116(6):627-36. (PMID: 17638930)
J Am Coll Cardiol. 2010 Jan 26;55(4):283-93. (PMID: 20117431)
Int J Epidemiol. 2020 Feb 1;49(1):193-204. (PMID: 30945727)
Int J Cardiol. 2023 May 15;379:66-75. (PMID: 36907452)
Intern Med. 2020 Nov 1;59(21):2639-2640. (PMID: 32669508)
Front Endocrinol (Lausanne). 2024 Jan 22;14:1322445. (PMID: 38317716)
JAMA. 2019 Oct 01;322(13):1271-1282. (PMID: 31475297)
Trends Pharmacol Sci. 2011 Dec;32(12):734-9. (PMID: 21880378)

Keywords: Heart failure; Overweight/obesity; Triglyceride-glucose index; Triglyceride-to-high-density lipoprotein cholesterol ratio

0 (Blood Glucose)
0 (Cholesterol, HDL)
0 (Triglycerides)

Date Created: 20240427 Date Completed: 20240428 Latest Revision: 20240523

20240523

PMC11055335

10.1186/s12944-024-02114-z

38678275